Literature DB >> 29234640

ALBI Score as a Novel Tool in Staging and Treatment Planning for Hepatocellular Carcinoma: Is It Sufficient?

Teh-Ia Huo1,2,3, Po-Hong Liu2,4, Chia-Yang Hsu2,5.   

Abstract

Entities:  

Year:  2017        PMID： 29234640      PMCID： PMC5704681          DOI： 10.1159/000481211

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  5 in total

1.  Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma.

Authors:  Anthony W H Chan; Takshi Kumada; Hidenori Toyoda; Toshifumi Tada; Charing C N Chong; Frankie K F Mo; Winnie Yeo; Philip J Johnson; Paul B S Lai; Anthony T C Chan; Ka-Fai To; Stephen L Chan
Journal:  J Gastroenterol Hepatol       Date:  2016-07       Impact factor: 4.029

2.  Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications.

Authors:  Atsushi Hiraoka; Takashi Kumada; Masatoshi Kudo; Masashi Hirooka; Kunihiko Tsuji; Ei Itobayashi; Kazuya Kariyama; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Toshifumi Tada; Hidenori Toyoda; Kazuhiro Nouso; Kouji Joko; Hideki Kawasaki; Yoichi Hiasa; Kojiro Michitaka
Journal:  Liver Cancer       Date:  2017-03-09       Impact factor: 11.740

3.  ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era.

Authors:  Po-Hong Liu; Chia-Yang Hsu; Cheng-Yuan Hsia; Yun-Hsuan Lee; Yi-You Chiou; Yi-Hsiang Huang; Fa-Yauh Lee; Han-Chieh Lin; Ming-Chih Hou; Teh-Ia Huo
Journal:  J Gastroenterol Hepatol       Date:  2017-04       Impact factor: 4.029

4.  Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems.

Authors:  Po-Hong Liu; Chia-Yang Hsu; Cheng-Yuan Hsia; Yun-Hsuan Lee; Chien-Wei Su; Yi-Hsiang Huang; Fa-Yauh Lee; Han-Chieh Lin; Teh-Ia Huo
Journal:  J Hepatol       Date:  2015-11-11       Impact factor: 25.083

5.  The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma.

Authors:  David J Pinato; Rohini Sharma; Elias Allara; Clarence Yen; Tadaaki Arizumi; Keiichi Kubota; Dominik Bettinger; Jeong Won Jang; Carlo Smirne; Young Woon Kim; Masatoshi Kudo; Jessica Howell; Ramya Ramaswami; Michela E Burlone; Vito Guerra; Robert Thimme; Mitsuru Ishizuka; Justin Stebbing; Mario Pirisi; Brian I Carr
Journal:  J Hepatol       Date:  2016-09-24       Impact factor: 25.083
  5 in total
  2 in total

Review 1.  Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis.

Authors:  Gauri Mishra; Ammar Majeed; Anouk Dev; Guy D Eslick; David J Pinato; Hirofumi Izumoto; Atsushi Hiraoka; Teh-Ia Huo; Po-Hong Liu; Philip J Johnson; Stuart K Roberts
Journal:  J Gastrointest Cancer       Date:  2022-05-30

Review 2.  Intraarterial Therapies for the Management of Hepatocellular Carcinoma.

Authors:  Tushar Garg; Apurva Shrigiriwar; Peiman Habibollahi; Mircea Cristescu; Robert P Liddell; Julius Chapiro; Peter Inglis; Juan C Camacho; Nariman Nezami
Journal:  Cancers (Basel)       Date:  2022-07-10       Impact factor: 6.575
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.